The House today voted to approve the Protect Medical Innovation Act—legislation that would repeal the 2.3% tax on medical devices imposed by the Affordable Care Act. The repeal would be effective for sales in calendar quarters beginning after the date of enactment (i.e., the legislation would be prospective).
The legislation is: H.R. 160 [PDF 254 KB]
The Joint Committee on Taxation has estimated that the legislation would lose approximately $24.4 billion in revenue over a 10-year period. Read the JCT revenue estimate.
The legislation does not include any provisions to offset the cost of repealing the medical device excise tax.
The Senate has not yet scheduled action on similar medical device excise tax repeal legislation.
The White House has issued a Statement of Administration Policy (SAP) [PDF 290 KB] stating that, if the president were presented with H.R. 160, his senior advisors would recommend that he veto the bill. The SAP states that H.R. 160 “would increase the deficit to finance a permanent and costly tax break for the industry without improving the health system or helping middle-class Americans.”
© 2017 KPMG LLP, a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity. All rights reserved.
The KPMG logo and name are trademarks of KPMG International. KPMG International is a Swiss cooperative that serves as a coordinating entity for a network of independent member firms. KPMG International provides no audit or other client services. Such services are provided solely by member firms in their respective geographic areas. KPMG International and its member firms are legally distinct and separate entities. They are not and nothing contained herein shall be construed to place these entities in the relationship of parents, subsidiaries, agents, partners, or joint venturers. No member firm has any authority (actual, apparent, implied or otherwise) to obligate or bind KPMG International or any member firm in any manner whatsoever. The information contained in herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.